Big Pharma has skirted long Covid, but a pipeline of small biotechs is testing treatments for lingering symptoms
Long Covid has been partly mysterious, due to the nascency of SARS-CoV-2 as well as the vastness of lingering symptoms experienced by millions of people worldwide following their initial diagnoses.
That makes long Covid quite a wide umbrella term and has led to a large gap in R&D, as it appears there’s a general unwillingness of most biopharmas to consider testing their drugs in this condition. For the most part, drugmakers interested in Covid-19 have most of their eggs in the prevention and acute treatment baskets through vaccines, monoclonal antibodies and antivirals.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters